The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
125386014 12538601 4 F 20140708 20160803 20160708 20160805 EXP CA-ROCHE-1419490 ROCHE 22.19 YR M Y 81.00000 KG 20160805 OT CA CA

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
125386014 12538601 1 PS ACTEMRA TOCILIZUMAB 1 Intravenous (not otherwise specified) B2043B04,B2048B16,B2033B07,B2032B14 125276 SOLUTION FOR INFUSION
125386014 12538601 2 SS ACTEMRA TOCILIZUMAB 1 Intravenous (not otherwise specified) B2043B04,B2048B16,B2033B07,B2032B14 125276 SOLUTION FOR INFUSION QOW
125386014 12538601 3 SS ACTEMRA TOCILIZUMAB 1 Intravenous (not otherwise specified) B2043B04,B2048B16,B2033B07,B2032B14 125276 680 MG SOLUTION FOR INFUSION QOW
125386014 12538601 4 SS ACTEMRA TOCILIZUMAB 1 Intravenous (not otherwise specified) B2043B04,B2048B16,B2033B07,B2032B14 125276 656 MG SOLUTION FOR INFUSION QOW
125386014 12538601 5 SS ACTEMRA TOCILIZUMAB 1 Intravenous (not otherwise specified) B2043B04,B2048B16,B2033B07,B2032B14 125276 640 MG SOLUTION FOR INFUSION QOW
125386014 12538601 6 SS ACTEMRA TOCILIZUMAB 1 Intravenous (not otherwise specified) B2043B04,B2048B16,B2033B07,B2032B14 125276 SOLUTION FOR INFUSION
125386014 12538601 7 SS ACTEMRA TOCILIZUMAB 1 Intravenous (not otherwise specified) B2043B04,B2048B16,B2033B07,B2032B14 125276 648 MG SOLUTION FOR INFUSION QOW
125386014 12538601 8 SS CEPHALEXIN. CEPHALEXIN 1 Oral 0
125386014 12538601 9 C NAPROSYN NAPROXEN 1 17581
125386014 12538601 10 C LOSEC OMEPRAZOLE 1 0
125386014 12538601 11 C PREDNISONE. PREDNISONE 1 0
125386014 12538601 12 C AERIUS (CANADA) 2 0
125386014 12538601 13 C FUCIDIN FUSIDIC ACID 1 Topical 0

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
125386014 12538601 1 Juvenile idiopathic arthritis
125386014 12538601 8 Localised infection

Outcome of event

Event ID CASEID OUTC COD
125386014 12538601 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
125386014 12538601 Blister
125386014 12538601 Blood pressure fluctuation
125386014 12538601 Blood pressure increased
125386014 12538601 Body temperature decreased
125386014 12538601 Ear infection
125386014 12538601 Gallbladder disorder
125386014 12538601 Heart rate decreased
125386014 12538601 Hypersensitivity
125386014 12538601 Hypotension
125386014 12538601 Infusion related reaction
125386014 12538601 Juvenile idiopathic arthritis
125386014 12538601 Lethargy
125386014 12538601 Localised infection
125386014 12538601 Nasopharyngitis
125386014 12538601 Oropharyngeal pain
125386014 12538601 Poor venous access
125386014 12538601 Rash
125386014 12538601 Weight decreased
125386014 12538601 Weight increased

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
125386014 12538601 1 2009 0
125386014 12538601 2 20131120 0
125386014 12538601 3 20131205 0
125386014 12538601 4 20140708 0
125386014 12538601 5 20140805 0
125386014 12538601 6 20141119 0
125386014 12538601 7 20150310 0